GeneDx Partners with Komodo Health to Revolutionize Rare Disease Data
1. Strategic Collaboration Aims to Enhance Patient Insights
On January 8, 2026, GeneDx Holdings Corp (Nasdaq: WGS) announced a groundbreaking partnership with Komodo Health, a leader in AI-powered healthcare intelligence, aimed at creating the world’s most complete longitudinal dataset for rare diseases. This strategic alliance promises to enhance the understanding of how rare diseases are diagnosed, managed, and treated, ultimately improving patient outcomes across the healthcare continuum.
2. GeneDx Infinity: A Game-Changer in Rare Disease Genomics
At the core of this collaboration is GeneDx’s Infinity™, the world’s largest rare disease genomic dataset, which has been built over 25 years of clinical experience. This extensive dataset encompasses over 2.5 million genetic tests focused on rare diseases and more than 7 million phenotypic data points. Notably, over 50% of the individuals represented in this dataset are of non-European ancestry, offering a diverse and comprehensive view of rare diseases.
“GeneDx Infinity is redefining what’s possible in rare disease,” stated Lisa Gurry, Chief Business Officer at GeneDx. By leveraging real-world patient insights from Komodo’s Healthcare Map®, this partnership aims to create a comprehensive longitudinal view that enhances healthcare economic outcomes research (HEOR) and advances biopharma innovation.
3. Komodo’s Healthcare Map: Bridging Genomic and Real-World Data
Komodo Health’s Healthcare Map is recognized as the industry’s most authoritative source of healthcare journeys for over 330 million de-identified patients. This collaboration will merge GeneDx’s genomic data with Komodo’s insights, including claims data from Medicare, Medicaid, and commercial insurance. By combining these datasets, the partnership seeks to illuminate real-world care pathways, treatment outcomes, and gaps in care at an unprecedented scale.
Miles Ennis, Chief Operating Officer of Komodo Health, emphasized the importance of this partnership in creating a connected view of genomic data and clinical practice. He remarked, “To meaningfully improve outcomes in rare disease, we must create a truly connected view of genomic data, clinical practice, and real-world evidence.”
4. High-Impact Use Cases for Biopharma and Healthcare
The combined dataset from GeneDx and Komodo will bolster several critical areas in healthcare, including:
- Health Economics and Outcomes Research (HEOR): Addressing the burden of disease, diagnostic journeys, and real-world treatment impacts.
- Research and Development: Enhancing target identification and patient stratification by connecting genomics with real-world care patterns.
- Clinical Trials: Facilitating faster cohort identification and feasibility assessments.
- Market Access and Value Demonstration: Strengthening engagement with payers and policymakers through real-world evidence.
- AI and Advanced Analytics: Leveraging high-quality, multimodal data to train AI models responsibly.
5. Accelerating Rare Disease Diagnosis and Treatment
GeneDx Infinity has experienced remarkable growth, generating 30% more exome and genome data in 2025 than in the previous 24 years combined. With nearly one million exomes and genomes sequenced and thousands of validated gene-disease associations, GeneDx is at the forefront of rare disease diagnosis. This partnership is set to further accelerate the path from data to discovery, ultimately leading to life-changing outcomes for patients.
6. Conclusion
As GeneDx and Komodo Health join forces, they are not only setting a new benchmark for rare disease intelligence but also redefining the landscape of genomic research and clinical practice. By merging extensive genomic data with real-world evidence, this partnership aims to revolutionize how rare diseases are understood, diagnosed, and treated, bringing hope to countless patients and their families.
